Last reviewed · How we verify
ACT-246475
At a glance
| Generic name | ACT-246475 |
|---|---|
| Also known as | Selatogrel |
| Sponsor | Viatris Innovation GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants (PHASE1)
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease (PHASE2)
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack (PHASE2)
- The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics (PHASE1)
- A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects (PHASE1)
- A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects (PHASE1)
- A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |